IL17A and Alzheimer disease: Figure 7B revealed not only the size of dLNs of AD mice with liquiritigenin was diminished compared to that of the dLNs of AD mice, but weight was also consistently reduced. To explore whether the expressions of effector cytokines were affected by the administration of liquiritigenin in AD, mRNA level of cytokines were checked from CD4+ T cells isolated from dLNs. Quantitative PCR results exhibited that effector cytokines exacerbating AD, including IL-4, IL-5, IL-13, IL-31, TNFα, and IL-17, were significantly decreased in group of AD mice with liquiritigenin (Figure 7C).